Épisodes

  • The MajesTEC-3 Trial in Myeloma
    Apr 12 2026

    Dr. Vincent Rajkumar of the Mayo Clinic joins the Healthcare Unfiltered EXPRESS to highlight a major study recently published in the NEJM concerning patients with R/R multiple myeloma. This study is arguably changing the standard of care for relapsed disease. We discussed the study, its rationale, its implications, and limitations.

    Here is a link to the actual publication: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663

    Please subscribe, rate, share, review, and join the conversation.

    Afficher plus Afficher moins
    11 min
  • Episode 49: Bladder Cancer Updates From ASCO GU 2026
    Mar 30 2026

    Dr. Andrea Apolo from the NCI and the co-Chair of the ASCO GU 2026 scientific program joined the Healthcare Unfiltered EXPRESS to share what she viewed as potentially practice-changing data in bladder cancer. She discussed what she viewed as the top 4 abstracts to be aware of.

    Stay up to date on all oncology meetings by subscribing to Healthcare Unfiltered EXPRESS; share with colleagues, and join the conversation.

    Afficher plus Afficher moins
    14 min
  • Episode 48: Renal and Prostate Cancer ASCO GU Updates
    Mar 20 2026

    Dr. Shilpa Gupta of Cleveland Clinic joins Healthcare Unfiltered EXPRESS to share three major abstracts from the ASCO-GU-2026 meeting that could change clinical practice in kidney and prostate cancers. Dr. Gupta brings this data home by explaining their impact on real-world practices. Check these out, subscribe, review, and join the conversation.

    Afficher plus Afficher moins
    15 min
  • Episode 47: The Approval of Zongertinib
    Mar 13 2026

    Dr. Eric Singhi of the MD Anderson Cancer Center joins Healthcare Unfiltered EXPRESS to describe this newly approved drug, its target, the trial that led to its approval, and how it fits into the treatment armamentarium for lung cancer. Please rate, subscribe, share, and join the conversation.

    Afficher plus Afficher moins
    10 min
  • Episode 46: Menin Inhibitors in AML
    Mar 5 2026

    Arguably, the development and approval of Menin Inhibitors in AML are one of the most important advances in this disease in the past 1-2 years. Dr. Uma Borate joins Healthcare Unfiltered EXPRESS and shares with us everything we must know about this class of drugs: how they are used, their toxicities, and what the future of AML management may look like now that we have Menin inhibitors. Check it out, subscribe, and review.

    Afficher plus Afficher moins
    16 min
  • Episode 45: The BRUIN-313 Trial in CLL
    Feb 22 2026

    Dr. Marc Braunstein from NYU Langone joins the Healthcare Unfiltered EXPRESS to describe the recently published BRUIN-313 trial in frontline CLL and its potential impact on the treatment landscape for this disease. Check it out, subscribe, share, and join the conversation.

    Afficher plus Afficher moins
    13 min
  • Episode 44: Burnout and AI
    Feb 12 2026

    Dr. Ishwaria Subbiah joined the Healthcare Unfiltered EXPRESS to discuss burnout, a problem physicians and many other healthcare providers face. She offers that AI and technology may bring solutions to reduce this problem and improve satisfaction. Check it out, subscribe, review, share, and join the conversation.

    Afficher plus Afficher moins
    12 min
  • Episode 43: The ASCENT-04 Trial in TNBC With Sara Tolaney
    Feb 9 2026

    Dr. Sara Tolaney of the Dana-Farber Cancer Institute joined the show to share her insights on the ASCENT-04 trial recently published in NEJM. This is an RCT in triple-negative breast cancer. Sara led this study and as the lead author, she puts its results in context - this is a must-listen episode. Please share, review, and subscribe.

    Afficher plus Afficher moins
    10 min